Last reviewed · How we verify
GLP-1 agonists
At a glance
| Generic name | GLP-1 agonists |
|---|---|
| Sponsor | Medical College of Wisconsin |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance (NA)
- Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists (NA)
- Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment (NA)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- RESCUE: Discontinuation of GLP-1
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-1 agonists CI brief — competitive landscape report
- GLP-1 agonists updates RSS · CI watch RSS
- Medical College of Wisconsin portfolio CI